Drugs

, Volume 64, Issue 22, pp 2503–2514

Medication Overuse Headache from Antimigraine Therapy

Clinical Features, Pathogenesis and Management
Therapy in Practice

Abstract

Medication overuse headache (MOH) is being recognised more often in headache, neurology and primary care clinics, but is still frequently overlooked. The most significant factor in the development of MOH is the lack of widespread awareness and understanding on the part of clinicians and patients. While the diagnosis of MOH may be suspected clinically, it can only be confirmed in retrospect. Diagnosis may take ≥3 months because of the need for prolonged observation after cessation of medication. Diagnosis must be based on observation of patterns of headaches and medication use, remembering that MOH is only seen in patients with migraine and not in those without.

MOH should be viewed as an entity that is caused or propagated by frequently used medication taken for headache symptomatic relief. Because of easy availability and low expense, the greatest problem appears to be associated with barbiturate-containing combination analgesics and over-the-counter caffeine-containing combination analgesics. Even though triptan overuse headache is not encountered with great frequency, all triptans should be considered potential inducers of MOH.

There are several different theories regarding the aetiology of MOH, including: (i) central sensitisation from repetitive activation of nociceptive pathways; (ii) a direct effect of the medication on the capacity of the brain to inhibit pain; (iii) a decrease in blood serotonin due to repetitive medication administration with attendant upregulation of serotonin receptors; (iv) cellular adaptation in the brain; and (v) changes in the periaqueductal grey matter.

The principal approach to management of MOH is built around cessation of overused medication. Without discontinuation of the offending medication, improvement is almost impossible to attain. A three-step approach to treating patients with analgesic rebound headaches includes: (i) a bridging or transition programme; (ii) nonpharmacological measures; and (iii) prophylactic medication started early in the course of treatment (after offending medication is successfully discontinued).

The best management advice is to raise awareness and strive for prevention. Prophylactic medications should be initiated for patients having ≥2 headache days per week. Anticipatory medication use should be discouraged and migraine-specific therapy should be considered as early as possible in the natural history of patients’ headaches. Reduction in headache risk factors should include behavioural modification approaches to headache control earlier in the natural history of migraine.

References

  1. 1.
    Scherer A, Stewart W, Liberman J, et al. Prevalence of frequent headache in a population sample. Headache 1998; 38: 497–506CrossRefGoogle Scholar
  2. 2.
    Mathew N. Transformed migraine. Cephalalgia 1993; 13: 78–83PubMedGoogle Scholar
  3. 3.
    Dreisbach RH. Experimental caffeine withdrawal headache. J Pharmacol Exp Ther 1940; 69: 283Google Scholar
  4. 4.
    Wolfson WQ, Graham JR. Development of tolerance to ergot alkaloids in a patient with unusually severe migraine. N Engl J Med 1949; 241: 296–8PubMedCrossRefGoogle Scholar
  5. 5.
    Peters GA, Horton BT. Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects. Mayo Clin Proc 1951; 26: 153–61Google Scholar
  6. 6.
    Kudrow L. Paradoxical effects of frequent analgesic use. Adv Neurol 1982; 33: 335–41PubMedGoogle Scholar
  7. 7.
    Isler H. Migraine treatment as a cause of chronic migraine. In: Rose F, editor. Advances in migraine research and therapy. New York: Raven Press, 1982: 159–64Google Scholar
  8. 8.
    Rapoport AM, Weeks RE, Sheftell FD, et al. The ‘analgesic washout period’: a critical variable in the evaluation of headache treatment efficacy [abstract]. Neurology 1986; 36 Suppl. 2: 100–1Google Scholar
  9. 9.
    Diener HC, Gerber WD, Geiselhart S, et al. Short and long term effects of withdrawal therapy in drug-induced headache. In: Diener HC, Wilkinson M, editors. Drug-induced headache. New York: Springer-Verlag, 1988: 133–42CrossRefGoogle Scholar
  10. 10.
    Gobel H, Stolze H, Heinze A, et al. Easy therapeutical management of sumatriptan-induced daily headache. Neurology 1996; 47: 297–8PubMedCrossRefGoogle Scholar
  11. 11.
    Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia 2004; 24 Suppl. 1: 9–160Google Scholar
  12. 12.
    Silberstein S, Lipton R, Goadsby P. The pathophysiology of primary headache. In: Silberstein S, Lipton R, Goadsby P, editors. Headache in clinical practice. London: Martin Dunitz Ltd, 2002: 57Google Scholar
  13. 13.
    Fields H, Heinricher M. Brainstem modulation of nociceptor-driven withdrawal reflexes. Ann N Y Acad Sci 1989; 563: 34–44PubMedCrossRefGoogle Scholar
  14. 14.
    Silberstein S, Lipton R. Chronic daily headache. In: Silberstein S, Lipton R, Dalessio D, editors. Wolff’s headache and other head pain. New York: Oxford University Press, 2001: 260–7Google Scholar
  15. 15.
    Srikiatkhachorn A, Tarasub N, Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache 2000; 40: 343–50PubMedCrossRefGoogle Scholar
  16. 16.
    Hering R, Glover V, Pattichis K, et al. 5HT in migraine patients with medication-induced headache. Cephalalgia 1993; 13: 410–2PubMedCrossRefGoogle Scholar
  17. 17.
    Mathew N. Migraine transformation and chronic daily headache. In: Cady RK, Fox AW, editors. Treating the headache patient. New York: Marcel Dekker, 1995: 75–100Google Scholar
  18. 18.
    Srikiatkhachorn A, Maneesri S, Govitrapong P, et al. Derangement of serotonin system in migrainous patients with analgesic abuse headache: clues from platelets. Headache 1998; 38: 43–9PubMedCrossRefGoogle Scholar
  19. 19.
    Welch K, Nagesh V, Aurora S, et al. Periaqueductal gray matter dysfunction in migraine: cause or burden of illness? Headache 2001; 41: 629–37PubMedCrossRefGoogle Scholar
  20. 20.
    Mathew N, Kurman R, Perez F. Drug induced refractory headache-clinical features and management. Headache 1990; 30: 634–8PubMedCrossRefGoogle Scholar
  21. 21.
    Lance E, Parkes C, Wilkinson M. Does analgesic abuse cause headaches de novo? Headache 1988; 28: 61–2PubMedCrossRefGoogle Scholar
  22. 22.
    Limmroth V, Katsarva A, Fritsch G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011–4PubMedCrossRefGoogle Scholar
  23. 23.
    Bowdler I, Kilian J. The association between analgesic abuse and headache: coincidental or causal [letter]. Headache 1988; 28(7): 494PubMedCrossRefGoogle Scholar
  24. 24.
    Raskin N. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986; 36: 995–7PubMedCrossRefGoogle Scholar
  25. 25.
    Smith T. Low-dose tizanidine with non-steroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache 2002; 42: 175–7PubMedCrossRefGoogle Scholar
  26. 26.
    Drucker P, Tepper S. Daily sumatriptan for detoxification from rebound. Headache 1998; 38: 687–90PubMedCrossRefGoogle Scholar
  27. 27.
    Sheftell F, Rapoport A, Coddon D. Naratriptan in the prophylaxis of transformed migraine. Headache 1999; 39: 506–10PubMedCrossRefGoogle Scholar
  28. 28.
    Bonuccelli U, Nuti A, Lucetti C, et al. Amitriptyline and dexamethasone combined treatment in drug induced headache. Cephalalgia 1996; 16: 197–200CrossRefGoogle Scholar
  29. 29.
    Ward T. Medication overuse headache. Prim Care Clin Office Pract 2004;31: 359–80CrossRefGoogle Scholar
  30. 30.
    Grazzi L, Andrasik F, D’Amico D, et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache 2002; 42: 483–90PubMedCrossRefGoogle Scholar
  31. 31.
    Suhr B, Ebers S, Bauer B, et al. Drug induced headache: long-term results of stationary versus ambulatory therapy. Cephalalgia 1999; 19: 44–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Ryan Headache CenterMercy Health ResearchSt LouisUSA

Personalised recommendations